An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products

Journal of Interferon and Cytokine Research

Volumn 31, Issue 4, 2011, Pages 383-392

  Meager, Anthony ^a   Dolman, Carl ^a   Dilger, Paula ^a   Bird, Chris ^a   Giovannoni, Gavin ^b   Schellekens, Huub ^c   Thorpe, Robin ^a   Wadhwa, Meenu ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BLASTOFERON; CINNOVEX; CLAUSEN; HUMAN SERUM ALBUMIN; JUMTAB; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IRAN; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; PATIENT SAFETY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOUTH AND CENTRAL AMERICA;

BIOLOGICAL ASSAY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUGS, GENERIC; HUMANS; IMMUNOBLOTTING; INTERFERON-BETA;

EID: 79953250278     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0113     Document Type: Article

References (43)

1. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. 2006. Structurefunction engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 17:618-630. (Pubitemid 43794371)
2. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P. 2004. Immunogenicity of interferon beta: differences among products. J Neurol 251 (Suppl. 2):II15-II24.
3. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634-639. (Pubitemid 36246082)
4. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin- Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475. (Pubitemid 34441737)
5. Clerico M, Contessa G, Durelli L. 2007. Interferon-beta1-a for the treatment of multiple sclerosis. Expert Opin Biol Ther 7:535-542.
6. Combe C, Tredree RL, Schellekens H. 2005. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 25(7):954-962. (Pubitemid 40917928)
7. Däubener W, Waganat N, Pilz K, Seghrouchni S, Fischer HG, Haddin U. 1994. A new, simple, bioassay for human IFN-γ. J Immunol Methods 168:39-47.
8. Deisenhammer F. 2009. Neutralizing antibodies to interferonbeta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 23: 379-396.
9. European Medicines Agency. Guideline on similar biological medicinal products. 2005. Available at www.emea.europa.eu/pdfs/human/biosimilar/043704en. pdf
10. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2006a. Available at www.emea.europa.eu/pdfs/human/biosimilar/4934805en. pdf
11. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006b. Available at www.emea.europa.eu/pdfs/ human/biosimilar/4283205en.pdf
12. Farrell RA, Giovannoni G. 2007. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler 13:567-577. (Pubitemid 46939521)
13. Fotiou F, Aravind S, Wang PP, Nerapusee O. 2009. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 31:336-346.
14. Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group. 2009. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 15:219-228.
15. Gneiss C, Koudouovoh-Tripp PM, Ropele S, Gotwald T, Ehling R, Lutterotti A, Aichner F, Ladurner G, Eggers C, Schautzer F, Künz B, Millonig A, Aspeck E, Reindl M, Berger T, Fazekas F, Deisenhammer F. 2009. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study (ASS). Mult Scler 15:1481-1488.
16. Goodin DS. 2005. Treatment of multiple sclerosis with human beta interferon. Int MS J 12:96-108. (Pubitemid 41712027)
17. Hochuli E. 1997. Interferon immunogenicity: technical evaluation of interferon-a2a. J Interferon Cytokine Res 17 (Suppl. 1):S15-S21. (Pubitemid 27327279)
18. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, and others. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294.
19. Kauffman M, Papouchodo M, Gonzalez E, Sterin Prync A, Vidal A, Diez R, Ferro H. 2008. Early post-marketing pharmacovigilance of Blastoferon: an interferon beta 1a biosimilar. Drug Saf 31(10):895.
20. Keithi-Reddy SR, Kandasamy S, Singh AK. 2008. Pure red cell aplasia due to follow-on epoetin. Kidney Int 74:1617-1622.
21. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng T, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roschke V, Chen G, Ruben SM, Coleman TA, Moore PA. 2001. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276:39765-39771.
22. Lam S, Wang S, Gottesman M. 2008. Interferon-b1b for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 4:1111-1117.
23. McKay F, Schibeci S, Heard R, Stewart G, Booth D. 2006. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australian cohort. J Immunol Methods 310:20-29.
24. Meager A. 2002. Biological assays for interferons. J Immunol Methods 261:21-36. (Pubitemid 34175214)
25. Meager A. 2003. Assays for antiviral activity. Methods Mol Biol 249:121-134.
26. Meager A, Gaines Das R. 2005. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta. J Immunol Methods 306:1-15.
27. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. 2005. Biological activity of interleukins-28 and -29: comparison with type I IFNs. Cytokine 31:109-118. (Pubitemid 40910226)
28. Mellstedt H, Niederwieser D, Ludwig H. 2008. The challenge of biosimilars. Ann Oncol 19(3):411-419. (Pubitemid 351325660)
29. Namaka M, Pollitt-Smith M, Gupta A, Klowak M, Vasconcelos M, Turcotte D, Gong Y, Melanson M. 2006. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin 22:223-239. (Pubitemid 44296747)
30. Pachner AR, Cadavid D, Wolansky L, Skurnick J. 2009. Effect of anti-IFN {beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 73:1485-1492.
31. Pachner A, Narayan K, Pak E. 2006. Multiplex analysis of expression of three IFN-β genes in antibody-positive MS patients. Neurology 66:444-446. (Pubitemid 43739958)
32. PRISMS (Prevention of Relapses and Disability for Interferon beta-1a subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised doulble-blind placebo-controlled study of interferon beta-1a in relapsing multiple sclerosis. Lancet 352:1498-1504.
33. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-b (IFN-β). Pharm Res 15:641-649.
34. Ryff J-C. 1997. Clinical investigation of the immunogenicity of interferon-α2a. J Interferon Cytokine Res 17 (Suppl. 1):S29-S33.
35. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2):53-59.
36. Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G. 2007. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 254:597-604.
37. Schellekens H. 2004. How similar do "biosimilars" need to be? Nat Biotechnol 22(11):1357-1359.
38. Schellekens H. 2009. Biosimilar therapeutics-what do we need to consider? NDT Plus 2 (Suppl. 1):i27-i36.
39. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. 2007. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13:208-214. (Pubitemid 46592773)
40. van der Voort LF, Visser A, Knol DL, Oudejans CB, Polman CH, Killestein J. 2009. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 16:1049-1052.
41. Wadhwa M, Thorpe R. 2007. Unwanted immunogenicity: implications for follow-on biologicals. Drug Inf J 41:1-10. (Pubitemid 46146055)
42. Wadhwa M, Thorpe R. 2009. The challenges of immunogenicity in developing biosimilar products. IDrugs 12(7):440-444.
43. WHO. 2009. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available at www.who.int/entity/biologicals/publications/trs/areas/ biological-therapeutics/BS2110Dft-guidelines-Final-HK-IK-29July-09.pdf